Stada Arz expands specialty footprint through acquisition of Lobsor Pharma

2 October 2020

German drugmaker Stada Arzneimittel (SAZ: Xetra) has strengthened its footprint in specialty pharmaceuticals by acquiring privately-held Swedish drugmaker Lobsor Pharmaceuticals and its innovative therapy used for treating late-stage Parkinson’s disease.

The infusion of levodopa, carbidopa and entacapone, marketed as Lecigon, is already approved in Sweden, Denmark, Norway and Finland, and Stada is currently submitting approval applications to launch the therapy in a number of major European markets.

Lobsor’s option has the advantage of being more lightweight than market sector leader AbbVie’s (NYSE: ABBV) Duodopa (levodopa/carbidopa) product, which is now more than 12 years old.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK